Evidence map›Paper›PMID 40615741›Full record

ArticleLung2025

The Advantages of FEV

James Dean, Augusta Beech, Dave Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

James DeanDivision of Immunology, Immunity to infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK. jdean@meu.org.uk.ORCID http://orcid.org/0000-0003-1657-3885
Augusta BeechDivision of Immunology, Immunity to infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.
Dave SinghDivision of Immunology, Immunity to infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe methacholine challenge requires a 20% fall in forced expiratory volume in one second (FEV

methodsChallenge data from a cohort of 114 asthma patients was re-analysed. The dose causing an 20% fall from baseline (PD

resultsThere was significant agreement between PD

conclusionWe suggest a PD criteria based on 15% predicted change should be used for bronchial challenge testing. This method is less influenced by baseline airflow obstruction, and is a more efficient and safer way of measuring airway hyperresponsiveness.

Indexed as

AsthmaBronchial HyperreactivityBronchial Provocation TestsBronchoconstrictor AgentsLungMethacholine ChlorideAdultAgedFemaleForced Expiratory VolumeHumansMaleMiddle AgedPredictive Value of TestsBronchoconstrictor AgentsMethacholine ChlorideAsthmaBronchial challengeHyperresponsivenessMethacholinePercent predicted

Identifiers

PMID40615741
PMCPMC12227454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.